The Progeria Research Foundation and Forge Biologics Announce Manufacturing Partnership to Advance Gene Therapy for Children with Progeria The Progeria Research Foundation (“PRF”), a nonprofit research organization dedicated to developing treatments and the cure for Hutchinson-Gilford Progeria Syndrome (“Progeria”), and…
Kivu Bioscience Names Brunilda Shtylla as Chief Business Officer to Lead Strategic Growth and Partnership Initiatives Kivu Bioscience, a clinical-stage biotechnology company dedicated to advancing next-generation antibody-drug conjugates (ADCs) for the treatment of difficult-to-treat cancers, has announced the appointment of…
Intellia Therapeutics Reports FDA Clearance to Resume MAGNITUDE Phase 3 Study in ATTR-CM Following Removal of Clinical Hold Intellia Therapeutics has cleared a significant regulatory hurdle in its effort to advance CRISPR-based gene editing into late-stage cardiovascular medicine, announcing that…
AbbVie Reports Positive Phase 3 Results for Subcutaneous SKYRIZI® in Crohn’s Disease AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3, randomized, placebo-controlled, double-blind AFFIRM study evaluating the efficacy and safety of risankizumab (SKYRIZI®) subcutaneous (SC) induction…
Pivotal Study Shows Significant Improvements in Hematocrit Control and Patient Outcomes What does the future hold for patients with polycythemia vera (PV)? Takeda and Protagonist Therapeutics, Inc. have announced a significant milestone in the treatment of this rare blood disorder.…
Cryo-Cell International Sees Revenue Dip and Net Loss in Fiscal 2025 What does a year of financial downturn mean for the world’s first private cord blood bank? Cryo-Cell International, Inc. a pioneer in cord blood and cord tissue cryopreservation, has…
Strategic Equity Incentives to Attract Talent and Drive Innovation Why is attracting and retaining top talent crucial for precision oncology companies? Guardant Health, a leading precision oncology company, is taking proactive steps to secure its workforce by granting equity awards…
Prothena’s Strategic Move to Boost Shareholder Confidence and Financial Flexibility Why are biotechnology companies increasingly turning to share repurchase plans to optimize their financial strategies? Prothena Corporation plc, a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics,…
Sarepta Supports Educational Ambitions of Duchenne Community with $5,000 Scholarships Why is supporting the education of individuals with Duchenne muscular dystrophy crucial for the future of rare disease treatment? Sarepta Therapeutics, a leader in precision genetic medicine for rare diseases,…
Quanta System Establishes U.S. Entity to Enhance Market Responsiveness and Customer Engagement Why is the U.S. market pivotal for Italian companies in the medical technology sector? Quanta System Sp.A., a leader in laser technologies for surgery, dermatology, and aesthetic medicine,…
Sun Nuclear Introduces Daily QA 4 Pro to Enhance Machine Quality Assurance in Cancer Care Why is the future of cancer care quality and patient safety becoming increasingly critical for medical physicists and radiation therapy professionals? Sun Nuclear, a Mirion…
Collaboration Aims to Overcome Delivery Challenges for Neurological Disorders Why has gene editing for Rett syndrome remained elusive despite its potential to reverse symptoms? Evox Therapeutics Ltd (Evox), a biotechnology company focused on developing innovative therapies for genetically driven neurodegenerative…
